Omnicell(OMCL)2025-05-06 10:34Financial Performance - Total revenues for Q1 2025 were $270 million, an increase of $24 million or 10% compared to Q1 2024, driven by growth in the XT Amplify program and SaaS services [3]. - Non-GAAP net income for Q1 2025 was $12 million, or $0.26 per diluted share, compared to $1 million, or $0.03 per diluted share in Q1 2024 [4]. - Non-GAAP EBITDA for Q1 2025 was $24 million, up from $11 million in Q1 2024 [5]. - Total revenues for Q1 2025 reached $269.7 million, a 9.5% increase from $246.2 million in Q1 2024 [29]. - Gross profit for Q1 2025 was $110.9 million, compared to $92.6 million in Q1 2024, reflecting a gross margin improvement [29]. - Net loss for Q1 2025 was $7.0 million, a reduction from a net loss of $15.7 million in Q1 2024, indicating improved operational efficiency [29]. - Non-GAAP net income for Q1 2025 was $12,354,000, significantly higher than $1,220,000 in Q1 2024 [39]. - Non-GAAP EBITDA for Q1 2025 reached $23,593,000, compared to $10,837,000 in Q1 2024, reflecting a non-GAAP EBITDA margin of 8.7% versus 4.4% [39]. - The company generated $25,924,000 in net cash from operating activities in Q1 2025, down from $49,953,000 in Q1 2024 [41]. - Non-GAAP free cash flow for Q1 2025 was $10,185,000, a decrease from $37,613,000 in Q1 2024 [41]. - The company reported a net loss of $7,023,000 for Q1 2025, an improvement from a net loss of $15,676,000 in Q1 2024 [35]. Balance Sheet and Cash Flow - As of March 31, 2025, cash and cash equivalents totaled $387 million, with total debt of $341 million and total assets of $2.2 billion [6]. - Cash and cash equivalents increased to $386.8 million as of March 31, 2025, up from $369.2 million at the end of 2024 [31]. - Total assets grew to $2.15 billion as of March 31, 2025, compared to $2.12 billion at the end of 2024, indicating solid asset management [31]. - Total stockholders' equity increased to $1.26 billion as of March 31, 2025, from $1.24 billion at the end of 2024, reflecting positive shareholder value [33]. - Omnicell has $350 million available under its revolving credit facility with no outstanding balance as of March 31, 2025 [7]. - The company’s total cash, cash equivalents, and restricted cash at the end of Q1 2025 was $414,402,000, down from $549,962,000 at the end of Q1 2024 [35]. Operational Efficiency and Cost Management - The company is focusing on mitigating potential tariff impacts on its supply chain while maintaining strong free cash flow [2]. - Omnicell plans to maintain its focus on operational efficiency and cost management while pursuing growth opportunities in the market [24]. - Research and development expenses decreased to $20.5 million in Q1 2025 from $22.1 million in Q1 2024, showing a focus on cost management [29]. - The company’s GAAP operating expenses were $122,555,000 in Q1 2025, representing 45.4% of total revenues, compared to 46.5% in Q1 2024 [37]. - Share-based compensation expense increased to $10,786,000 in Q1 2025 from $8,641,000 in Q1 2024 [39]. Future Guidance and Investments - The company updated its full-year 2025 guidance, projecting total revenues between $1.105 billion and $1.155 billion [10]. - Annual recurring revenue is expected to be between $610 million and $630 million for 2025 [10]. - The company continues to invest in research and development to enhance product offerings and market competitiveness [23]. - The company plans to open the Austin Innovation Lab on May 14, 2025, to enhance product development and innovation [15].